Studies have shown that targeting cancer metabolism is effective in tumors harboring different mutations in either oncogenes (e.g. MYC, PIK3CA, etc.)or tumor suppressors (e.g. TP53, PTEN, LKB1, etc.)[12–14], likely because those genetic alterations are actively involved in the metabolic process and control the metabolic rewiring of cancer cells [15]. The gene discussed is STK11; the disease is neoplasm.